Integrated Imaging Visikol is a contract research services firm offering end-to-end tissue imaging and cell culture services to accelerate drug discovery, with capabilities including 3D tissue imaging, multiplex imaging, digital pathology, high content imaging, 2D/3D cell culture assays, and ex vivo tissue slices; they convert tissue data into actionable insights and bridge in vitro to in vivo with advanced cell culture models; this breadth presents cross-sell opportunities to top pharma clients for more comprehensive, integrated studies.

BBB CNS Opportunity Recent initiatives include development of BBB permeability assays and BBB models, indicating a focus on CNS delivery; these offerings align with a likely need from pharma for CNS programs to quantify penetration, mechanisms, and effects on barrier integrity; target CNS drug developers across top pharma and biotech.

GLP Multiplex Expansion Visikol launched GLP multiplex tissue imaging services, enabling GLP-compliant imaging studies for regulatory submissions; sales angle: pitch to teams needing regulated imaging data, IND-enabling studies, potentially cross-sell with their existing imaging mass cytometry service and tissue slices.

Strategic Partnerships Partnerships with Standard BioTools expanded imaging capabilities, including Imaging Mass Cytometry; this collaboration suggests opportunities to co-sell to Standard BioTools' customers and to leverage partner channels to reach more pharma clients, especially in deep phenotyping and multiplex analyses.

Liver & Slices Upsell Visikol sells HUREL Micro Liver primary hepatocyte models and a suite of precision cut tissue slice models (kidney and liver) which can address hepatotoxicity, metabolism, and organ-specific studies; this offers upsell opportunities to pharma programs requiring metabolic and DILI assessment, complementing imaging data across translational studies.